Cargando…
Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis
Autores principales: | Li, Guo-Fu, An, Xiao-Xiao, Yu, Yichao, Jiao, Li-Rong, Canarutto, Daniele, Yu, Guo, Wang, Guangji, Wu, Dan-Na, Xiao, Yin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355875/ https://www.ncbi.nlm.nih.gov/pubmed/33172925 http://dx.doi.org/10.1136/gutjnl-2020-323366 |
Ejemplares similares
-
Proton pump inhibitor use associated with changes in gut microbiota composition
por: Reveles, Kelly R, et al.
Publicado: (2018) -
Proton pump inhibitors and the risk of gallbladder cancer: a hospital-based case–control study
por: Xiong, Jianping, et al.
Publicado: (2020) -
Response by Abrahami et al to letter regarding article ‘Proton pump inhibitors and risk of colorectal cancer’
por: Abrahami, Devin, et al.
Publicado: (2022) -
Proton pump inhibitors and gastric cancer: a long expected side effect finally reported also in man
por: Waldum, Helge Lyder, et al.
Publicado: (2018) -
Mechanistic insight of SARS-CoV-2 infection using human hepatobiliary organoids
por: Zhao, Yi, et al.
Publicado: (2023)